Related Experiment Video

Updated: Jul 19, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

The Bcl10/Malt1 signaling pathway as a drug target in lymphoma

P Jost1, C Peschel, J Ruland

  • 1Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany.

Current Drug Targets
|November 1, 2006
PubMed

Insights

Chromosomal translocations in MALT lymphoma dysregulate BCL10 and MALT1 signaling, activating NF-kappaB. This pathway

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Chromosomal translocations are key drivers in lymphoma and leukemia development.
  • Specific translocations in MALT lymphoma involve BCL10, MALT1, or API2-MALT1 fusions.
  • These aberrations disrupt cellular pathways regulating differentiation, proliferation, and survival.

Purpose of the Study:

  • To provide an overview of BCL10/MALT1 signal transduction in physiological and pathological contexts.
  • To discuss the therapeutic potential of targeting the BCL10/MALT1 pathway in MALT lymphoma.

Main Methods:

  • Review of genetic and biochemical experimental findings.
  • Analysis of signaling cascades involving BCL10 and MALT1.
  • Examination of NF-kappaB activation in response to antigen receptor ligation.

Main Results:

  • BCL10 and MALT1 are central to an oligomerization-ubiquitinylation-phosphorylation cascade.
  • This cascade activates the transcription factor NF-kappaB.
  • Dysregulation of this signaling pathway contributes to MALT lymphoma growth independent of antigen stimulation.

Conclusions:

  • The BCL10/MALT1 signaling pathway plays a critical role in MALT lymphoma pathogenesis.
  • Targeting this pathway offers a promising strategy for selective drug therapies in MALT lymphoma.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...